Previous 10 | Next 10 |
Plenary presentation of Phase 3 tislelizumab trial in first-line RM-NPC Primary analysis of zanubrutinib Phase 2 ROSEWOOD trial in follicular lymphoma Long-term data from zanubrutinib Phase 3 trial in Waldenström macroglobulinemia BeiGene (NASDAQ: BGNE; ...
Chinese biotech BeiGene (NASDAQ:BGNE) announced on Wednesday that a Phase 3 trial for the company’s anti-PD-1 inhibitor tislelizumab in combination with chemotherapy reached primary endpoint in a group of patients with esophageal squamous cell carcinoma (ESCC). The 649-patient RATIONAL...
Statistically significant and clinically meaningful improvement in overall survival achieved for tislelizumab and chemotherapy compared to placebo and chemotherapy Safety profile for the combination consistent with previous trials BeiGene (NASDAQ: BGNE; HKEX:...
Change Is the Cure™ , BeiGene’s ESG strategy and framework launched in 2021, defines the Company’s aspirational reason for thinking beyond its products and provides a path to help create a better world BeiGene, Ltd . (NASDAQ: BGNE; HK...
China-based biotechs, BeiGene (NASDAQ:BGNE) and Biocytogen Pharmaceuticals have reached an agreement for licensing Biocytogen's fully human antibody RenMab/RenLite mice platforms. Per the terms, the companies will leverage the potential of RenMab/RenLite to develop fully human monoclonal anti...
Biocytogen Signs RenMab™/RenLite™ Licensing Agreement with BeiGene Canada NewsWire BEIJING , April 25, 2022 /CNW/ -- Biocytogen Pharmaceuticals ( Beijing ) Co., Ltd. ("Biocytogen") reached an agreement with BeiGene ( Beijing ) Co., L...
BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines, and Crossroads4Hope, A Network of Cancer Support, a 501(c)(3) organization committed to transforming the cancer experience for pati...
BeiGene (NASDAQ:BGNE) said updated data from a phase 3 trial of tislelizumab plus chemotherapy showed progression-free survival (PFS) benefit in patients with a type of head and neck cancer. The company presented updated data — as of the cut of date Sept. 30, 2021 —...
Progression-Free Survival Benefit of Tislelizumab in Combination with Chemotherapy Sustained at Median 15.5 Month Follow-up Secondary Survival Endpoint Findings Were Consistent with Interim Analysis BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-...
BeiGene (NASDAQ:BGNE) and Novartis' (NVS) tislelizumab was approved by China's National Medical Products Administration (NMPA) to treat patients with locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have disease progression or are intolerant to first-line stan...
News, Short Squeeze, Breakout and More Instantly...
$800 million investment in New Jersey supports global growth and expansion with technologically advanced manufacturing capacity and clinical development capabilities for novel cancer medicines BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today ann...
2024-07-20 02:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BeiGene , Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Aaron Rosenberg as Chief Financial Officer, effective July 22. Mr. Rosenberg will succeed Julia Wang, who is departing to pursue external opportunities and will stay with the C...